The bill amends Minnesota Statutes 2024, section 152.126, to update the terminology used in the prescription monitoring program, changing "controlled substances" to "reportable substances." This change includes a definition of "reportable" substances, which now encompasses specific drugs like butalbital and FDA-approved opioid antagonists for overdose reversal. The amendments clarify the roles of dispensers and prescribers, indicating that dispensers are not required to report certain prescriptions under specific circumstances, such as those dispensed in healthcare facilities or as drug samples. Additionally, the bill outlines the reporting requirements for dispensers, detailing the data that must be submitted to the board and establishing guidelines for data use and access by prescribers, dispensers, and law enforcement.

Moreover, the bill introduces provisions to enhance data access and management related to opioid prescriptions and treatment programs. It restricts access to reportable data on opioid antagonists to specific users and mandates the board to maintain a log of all data access for at least three years, along with conducting random audits for compliance. The responsibilities of the commissioner of human services are also outlined, including the establishment of a system for routine data access to monitor clients in opioid treatment programs and the requirement to inform medical directors of any issues with multiple prescribers or prescriptions. Overall, these amendments aim to improve the effectiveness, accountability, and security of the prescription monitoring program while ensuring patient privacy.

Statutes affected:
Introduction: 152.126